G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer
Takayuki Iwamoto,Giampaolo Bianchini,Daniel J. Booser,Yuan Qi,Charles Coutant,Christine Y. Shiang,Libero Santarpia,Junji Matsuoka,Gabriel N. Hortobagyi,William Fraser Symmans,Frankie A. Holmes,Joyce O'Shaughnessy,Beth A. Hellerstedt,John Pippen,Fabrice Andre,Richard Simon,Lajos Pusztai +16 more
TL;DR: Different biological processes were associated with prognosis and chemotherapy response in ER-positive and ER-negative breast cancers.
Journal ArticleDOI
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
Heng Huan Lee,Ying Nai Wang,Wei Ya Xia,Chia-Hung Chen,Kun Ming Rau,Leiguang Ye,Yongkun Wei,Chao Kai Chou,Shao Chun Wang,Meisi Yan,Meisi Yan,Chih Yen Tu,Te Chun Hsia,Shu Fen Chiang,K. S. Clifford Chao,Ignacio I. Wistuba,Jennifer L. Hsu,Jennifer L. Hsu,Jennifer L. Hsu,Gabriel N. Hortobagyi,Mien Chie Hung +20 more
TL;DR: A method to resolve this by removing the glycan moieties from cell surface antigens via enzymatic digestion, a process termed sample deglycosylation, significantly improves anti-PD-L1 antibody binding affinity and signal intensity, resulting in more accurate PD-L 1 quantification and prediction of clinical outcome.
Journal ArticleDOI
Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy
Halle C. F. Moore,Joseph M. Unger,Kelly-Anne Phillips,Frances M. Boyle,Frances M. Boyle,Erika Hitre,David L. Porter,Prudence A. Francis,Lori J. Goldstein,Henry L. Gomez,Carlos S. Vallejos,Ann H. Partridge,Shaker R. Dakhil,Shaker R. Dakhil,Agustin A. Garcia,Julie R. Gralow,Janine M. Lombard,John F. Forbe,Silvana Martino,William E. Barlow,Carol J. Fabian,Lori M. Minasian,Frank L. Meyskens,Richard D. Gelber,Gabriel N. Hortobagyi,Kathy S. Albain +25 more
TL;DR: The survival benefit of adjuvant chemotherapy in young women with operable hormone receptor–negative breast cancer is well known, but concern over becoming infertile may influence the choice of treatment.
Journal ArticleDOI
Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial
Gabriel N. Hortobagyi,Naoto T. Ueno,Weiya Xia,Shizhen Zhang,J. K. Wolf,Joe B. Putnam,P. L. Weiden,Jie Willey,Mary Carey,D. L. Branham,J. Y. Payne,S. D. Tucker,Chandra Bartholomeusz,R. G. Kilbourn,R. L. De Jager,Nour Sneige,Ruth L. Katz,Pervin Anklesaria,Nuhad K. Ibrahim,James L. Murray,R. L. Theriault,V. Valero,David M. Gershenson,Michael W. Bevers,L. Huang,Gabriel Lopez-Berestein,Mien Chie Hung +26 more
TL;DR: The results argue for the feasibility of intracavitary DCC-E1A administration, provide a clear proof of preclinical concept, and warrant phase II trials to determine the antitumor activity of the E1A gene.
Journal ArticleDOI
Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency
Chien-Hsing Lu,Shannon L. Wyszomierski,Ling Ming Tseng,Ling Ming Tseng,Meng Hong Sun,Keng-Hsueh Lan,Keng-Hsueh Lan,Christopher L. Neal,Gordon B. Mills,Gabriel N. Hortobagyi,Francisco J. Esteva,Dihua Yu +11 more
TL;DR: Preclinical studies on the efficacy of clinically applicable inhibitors of the Akt/mammalian target of rapamycin (mTOR) pathway to restore trastuzumab sensitivity to PTEN-deficient cells and combinations of trastizumab with triciribine or RAD001 are promising regimens for rescue oftrastuzuab resistance caused by PTEN loss.